Advertisement

Related Videos

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Advertisement

Advertisement




Nov
07
Today In Oncology
FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma
Armando Giuliano Honored With 2025 William L. McGuire Memorial Lecture Award
Hepatic Arterial Infusion Pump Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma
Physician-Complementing Artificial Intelligence in Oncology
First-Line Ivonescimab or Tislelizumab Plus Chemotherapy in Advanced Squamous NSCLC
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo